25 XP   0   0   10

Isracann Biosciences Inc
Buy, Hold or Sell?

Let's analyse Isracann together

PenkeI guess you are interested in Isracann Biosciences Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Isracann Biosciences Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Isracann Biosciences Inc

I send you an email if I find something interesting about Isracann Biosciences Inc.

Quick analysis of Isracann (30 sec.)










What can you expect buying and holding a share of Isracann? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.00
Expected worth in 1 year
$-0.01
How sure are you?
20.9%

+ What do you gain per year?

Total Gains per Share
$-0.01
Return On Investment
-13,902.2%

For what price can you sell your share?

Current Price per Share
$0.00
Expected price per share
$0.0001 - $0.005
How sure are you?
50%

1. Valuation of Isracann (5 min.)




Live pricePrice per Share (EOD)

$0.00

Intrinsic Value Per Share

$-0.16 - $-0.11

Total Value Per Share

$-0.16 - $-0.11

2. Growth of Isracann (5 min.)




Is Isracann growing?

Current yearPrevious yearGrowGrow %
How rich?$91.3k$10.3m-$9.4m-1,011.5%

How much money is Isracann making?

Current yearPrevious yearGrowGrow %
Making money-$830.7k-$4.5m$3.6m444.5%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Isracann (5 min.)




What can you expect buying and holding a share of Isracann? (5 min.)

Welcome investor! Isracann's management wants to use your money to grow the business. In return you get a share of Isracann.

What can you expect buying and holding a share of Isracann?

First you should know what it really means to hold a share of Isracann. And how you can make/lose money.

Speculation

The Price per Share of Isracann is $0.0001. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Isracann.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Isracann, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.00. Based on the TTM, the Book Value Change Per Share is $0.00 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Isracann.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.00-1,314.1%0.00-4,720.4%-0.03-25,703.1%-0.01-10,644.8%-0.01-5,891.9%
Usd Book Value Change Per Share0.00-688.3%0.00-3,475.5%-0.02-23,225.8%0.0032.6%0.00-13.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.00-688.3%0.00-3,475.5%-0.02-23,225.8%0.0032.6%0.00-13.7%
Usd Price Per Share0.04-0.06-0.19-0.15-0.08-
Price to Earnings Ratio-7.23--5.14--7.75--7.89--4.22-
Price-to-Total Gains Ratio-55.21--28.22-49.07--0.99--0.99-
Price to Book Ratio73.17-33.69-5.49-3.82-2.04-
Price-to-Total Gains Ratio-55.21--28.22-49.07--0.99--0.99-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0001
Number of shares10000000
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (10000000 shares)-34,755.49326.48
Gains per Year (10000000 shares)-139,021.951,305.92
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-139022-139032013061296
20-278044-278054026122602
30-417066-417076039183908
40-556088-556098052245214
50-695110-695120065306520
60-834132-834142078357826
70-973154-973164091419132
80-1112176-111218601044710438
90-1251198-125120801175311744
100-1390219-139023001305913050

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.013.00.00.0%0.023.00.00.0%0.043.00.00.0%0.051.00.00.0%
Book Value Change Per Share0.04.00.00.0%2.011.00.015.4%7.016.00.030.4%9.033.01.020.9%10.040.01.019.6%
Dividend per Share0.00.04.00.0%0.00.013.00.0%0.00.023.00.0%0.00.043.00.0%0.00.051.00.0%
Total Gains per Share0.04.00.00.0%2.011.00.015.4%7.016.00.030.4%9.033.01.020.9%10.040.01.019.6%

Fundamentals of Isracann

About Isracann Biosciences Inc

Isracann Biosciences Inc., together with its subsidiaries, cultivates and distributes medical cannabis in Israel. The company also develops cultivation facilities. It exports its products to Germany. The company was formerly known as Atlas Blockchain Group Inc. and changed its name to Isracann Biosciences Inc. in October 2019. Isracann Biosciences Inc. was founded in 2010 and is headquartered in Vancouver, Canada.

Fundamental data was last updated by Penke on 2024-04-22 12:25:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Isracann Biosciences Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Isracann earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Isracann to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Isracann Biosciences Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-553.4%+553.4%
5Y-553.4%10Y-372.0%-181.3%
1.1.2. Return on Assets

Shows how efficient Isracann is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Isracann to the Drug Manufacturers - Specialty & Generic industry mean.
  • -7.8% Return on Assets means that Isracann generated $-0.08 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Isracann Biosciences Inc:

  • The MRQ is -7.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -30.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.8%TTM-30.6%+22.8%
TTM-30.6%YOY-126.6%+96.0%
TTM-30.6%5Y-118.8%+88.1%
5Y-118.8%10Y-69.1%-49.6%
1.1.3. Return on Equity

Shows how efficient Isracann is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Isracann to the Drug Manufacturers - Specialty & Generic industry mean.
  • -246.6% Return on Equity means Isracann generated $-2.47 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Isracann Biosciences Inc:

  • The MRQ is -246.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -309.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-246.6%TTM-309.9%+63.4%
TTM-309.9%YOY-141.3%-168.6%
TTM-309.9%5Y-90.5%-219.4%
5Y-90.5%10Y-61.1%-29.4%

1.2. Operating Efficiency of Isracann Biosciences Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Isracann is operating .

  • Measures how much profit Isracann makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Isracann to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Isracann Biosciences Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-963.2%+963.2%
5Y-963.2%10Y-584.9%-378.3%
1.2.2. Operating Ratio

Measures how efficient Isracann is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Isracann Biosciences Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y8.507-8.507
5Y8.50710Y5.491+3.017

1.3. Liquidity of Isracann Biosciences Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Isracann is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 0.30 means the company has $0.30 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Isracann Biosciences Inc:

  • The MRQ is 0.295. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.733. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.295TTM0.733-0.438
TTM0.733YOY3.450-2.717
TTM0.7335Y6.330-5.597
5Y6.33010Y8.588-2.258
1.3.2. Quick Ratio

Measures if Isracann is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Isracann to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.27 means the company can pay off $0.27 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Isracann Biosciences Inc:

  • The MRQ is 0.273. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.658. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.273TTM0.658-0.384
TTM0.658YOY3.201-2.544
TTM0.6585Y4.808-4.151
5Y4.80810Y7.743-2.935

1.4. Solvency of Isracann Biosciences Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Isracann assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Isracann to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.97 means that Isracann assets are financed with 96.9% credit (debt) and the remaining percentage (100% - 96.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Isracann Biosciences Inc:

  • The MRQ is 0.969. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.598. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.969TTM0.598+0.371
TTM0.598YOY0.076+0.522
TTM0.5985Y1.453-0.855
5Y1.45310Y0.917+0.536
1.4.2. Debt to Equity Ratio

Measures if Isracann is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Isracann to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 3,054.4% means that company has $30.54 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Isracann Biosciences Inc:

  • The MRQ is 30.544. The company is unable to pay all its debts with equity. -1
  • The TTM is 11.036. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ30.544TTM11.036+19.508
TTM11.036YOY0.084+10.952
TTM11.0365Y1.965+9.071
5Y1.96510Y1.651+0.315

2. Market Valuation of Isracann Biosciences Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Isracann generates.

  • Above 15 is considered overpriced but always compare Isracann to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -7.23 means the investor is paying $-7.23 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Isracann Biosciences Inc:

  • The EOD is -0.019. Based on the earnings, the company is expensive. -2
  • The MRQ is -7.229. Based on the earnings, the company is expensive. -2
  • The TTM is -5.138. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.019MRQ-7.229+7.210
MRQ-7.229TTM-5.138-2.091
TTM-5.138YOY-7.752+2.614
TTM-5.1385Y-7.888+2.750
5Y-7.88810Y-4.219-3.669
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Isracann Biosciences Inc:

  • The EOD is -0.037. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -13.980. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -11.357. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.037MRQ-13.980+13.943
MRQ-13.980TTM-11.357-2.623
TTM-11.357YOY-12.066+0.709
TTM-11.3575Y-10.412-0.945
5Y-10.41210Y-5.569-4.843
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Isracann is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Isracann Biosciences Inc:

  • The EOD is 0.193. Based on the equity, the company is cheap. +2
  • The MRQ is 73.174. Based on the equity, the company is expensive. -2
  • The TTM is 33.689. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.193MRQ73.174-72.982
MRQ73.174TTM33.689+39.486
TTM33.689YOY5.490+28.198
TTM33.6895Y3.821+29.868
5Y3.82110Y2.044+1.777
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Isracann Biosciences Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.001-0.003+405%-0.023+3275%0.000-2208%0.000-98%
Book Value Per Share--0.0010.005-90%0.059-99%0.055-99%0.030-98%
Current Ratio--0.2950.733-60%3.450-91%6.330-95%8.588-97%
Debt To Asset Ratio--0.9690.598+62%0.076+1176%1.453-33%0.917+6%
Debt To Equity Ratio--30.54411.036+177%0.084+36380%1.965+1454%1.651+1750%
Dividend Per Share----0%-0%-0%-0%
Eps---0.001-0.005+259%-0.026+1856%-0.011+710%-0.006+348%
Free Cash Flow Per Share---0.001-0.002+126%-0.004+504%-0.005+657%-0.003+329%
Free Cash Flow To Equity Per Share--0.000-0.001+1870%-0.002+4179%0.002-103%0.001-106%
Gross Profit Margin--1.0011.082-7%1.188-16%1.249-20%1.135-12%
Intrinsic Value_10Y_max---0.111--------
Intrinsic Value_10Y_min---0.165--------
Intrinsic Value_1Y_max---0.012--------
Intrinsic Value_1Y_min---0.019--------
Intrinsic Value_3Y_max---0.034--------
Intrinsic Value_3Y_min---0.056--------
Intrinsic Value_5Y_max---0.057--------
Intrinsic Value_5Y_min---0.090--------
Market Cap17599.000-37900%6687620.00010427407.500-36%34186057.500-80%26701508.870-75%14282202.419-53%
Net Profit Margin----0%-0%-5.5340%-3.7200%
Operating Margin----0%-0%-9.6320%-5.8490%
Operating Ratio----0%-0%8.507-100%5.491-100%
Pb Ratio0.193-37900%73.17433.689+117%5.490+1233%3.821+1815%2.044+3481%
Pe Ratio-0.019+100%-7.229-5.138-29%-7.752+7%-7.888+9%-4.219-42%
Price Per Share0.000-37900%0.0380.059-36%0.194-80%0.152-75%0.081-53%
Price To Free Cash Flow Ratio-0.037+100%-13.980-11.357-19%-12.066-14%-10.412-26%-5.569-60%
Price To Total Gains Ratio-0.145+100%-55.212-28.222-49%49.072-213%-0.987-98%-0.987-98%
Quick Ratio--0.2730.658-58%3.201-91%4.808-94%7.743-96%
Return On Assets---0.078-0.306+292%-1.266+1519%-1.188+1418%-0.691+784%
Return On Equity---2.466-3.099+26%-1.413-43%-0.905-63%-0.611-75%
Total Gains Per Share---0.001-0.003+405%-0.023+3275%0.000-2208%0.000-98%
Usd Book Value--91393.085930808.097-90%10345546.842-99%9602443.100-99%5310207.243-98%
Usd Book Value Change Per Share---0.001-0.003+405%-0.023+3275%0.000-2208%0.000-98%
Usd Book Value Per Share--0.0010.005-90%0.059-99%0.055-99%0.030-98%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.001-0.005+259%-0.026+1856%-0.011+710%-0.006+348%
Usd Free Cash Flow---119592.460-269930.026+126%-722576.509+504%-905911.834+657%-513423.373+329%
Usd Free Cash Flow Per Share---0.001-0.002+126%-0.004+504%-0.005+657%-0.003+329%
Usd Free Cash Flow To Equity Per Share--0.000-0.001+1870%-0.002+4179%0.002-103%0.001-106%
Usd Market Cap17599.000-37900%6687620.00010427407.500-36%34186057.500-80%26701508.870-75%14282202.419-53%
Usd Price Per Share0.000-37900%0.0380.059-36%0.194-80%0.152-75%0.081-53%
Usd Profit---231276.741-830747.303+259%-4523669.700+1856%-2303902.219+896%-1267194.758+448%
Usd Revenue----0%-0%74922.121-100%50866.607-100%
Usd Total Gains Per Share---0.001-0.003+405%-0.023+3275%0.000-2208%0.000-98%
 EOD+3 -5MRQTTM+17 -13YOY+15 -155Y+11 -2110Y+11 -21

3.2. Fundamental Score

Let's check the fundamental score of Isracann Biosciences Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.019
Price to Book Ratio (EOD)Between0-10.193
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.273
Current Ratio (MRQ)Greater than10.295
Debt to Asset Ratio (MRQ)Less than10.969
Debt to Equity Ratio (MRQ)Less than130.544
Return on Equity (MRQ)Greater than0.15-2.466
Return on Assets (MRQ)Greater than0.05-0.078
Total2/10 (20.0%)

3.3. Technical Score

Let's check the technical score of Isracann Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5024.931
Ma 20Greater thanMa 500.003
Ma 50Greater thanMa 1000.003
Ma 100Greater thanMa 2000.005
OpenGreater thanClose0.000
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2022-08-31. Currency in CAD. All numbers in thousands.

Summary
Total Assets4,040
Total Liabilities3,915
Total Stockholder Equity128
 As reported
Total Liabilities 3,915
Total Stockholder Equity+ 128
Total Assets = 4,040

Assets

Total Assets4,040
Total Current Assets304
Long-term Assets3,735
Total Current Assets
Cash And Cash Equivalents 198
Net Receivables 83
Other Current Assets 23
Total Current Assets  (as reported)304
Total Current Assets  (calculated)304
+/-0
Long-term Assets
Property Plant Equipment 37
Intangible Assets 3,698
Long-term Assets  (as reported)3,735
Long-term Assets  (calculated)3,735
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities1,030
Long-term Liabilities2,885
Total Stockholder Equity128
Total Current Liabilities
Accounts payable 635
Other Current Liabilities 395
Total Current Liabilities  (as reported)1,030
Total Current Liabilities  (calculated)1,030
+/-0
Long-term Liabilities
Other Liabilities 2,885
Long-term Liabilities  (as reported)2,885
Long-term Liabilities  (calculated)2,885
+/-0
Total Stockholder Equity
Common Stock63,101
Retained Earnings -77,138
Accumulated Other Comprehensive Income 14,118
Other Stockholders Equity 47
Total Stockholder Equity (as reported)128
Total Stockholder Equity (calculated)128
+/-0
Other
Capital Stock63,101
Cash and Short Term Investments 198
Common Stock Shares Outstanding 158,455
Liabilities and Stockholders Equity 4,040
Net Debt -198
Net Invested Capital 128
Net Tangible Assets -3,570
Net Working Capital -725



Balance Sheet

Currency in CAD. All numbers in thousands.

 Trend2022-08-312022-05-312022-02-282021-11-302021-08-312021-05-312021-02-282020-11-302020-08-312020-05-312020-02-292019-11-302019-09-302019-08-312019-06-302019-05-312019-03-312019-02-282018-11-302018-08-312018-05-312018-02-282017-11-302017-08-312017-05-312017-02-282016-11-302016-08-312016-05-312016-02-292015-11-302015-08-312015-05-312015-02-282014-11-302014-08-312014-05-312014-02-282013-11-302013-08-312013-05-312013-02-282012-11-302012-08-312012-05-312012-02-292011-11-302011-08-312011-05-312011-02-282010-11-302010-08-31
> Total Assets 
0
435
405
391
390
353
333
317
284
286
269
254
233
208
193
170
1,354
1,209
1,113
1,129
1,084
0
1,067
1,048
1,524
1,373
1,149
1,008
831
5,649
15,770
14,557
9,770
6,939
11,882
53
16,372
53
15,363
121
53,164
49,350
28,274
27,014
25,401
25,810
4,400
3,928
3,410
2,780
4,091
4,040
4,0404,0912,7803,4103,9284,40025,81025,40127,01428,27449,35053,16412115,3635316,3725311,8826,9399,77014,55715,7705,6498311,0081,1491,3731,5241,0481,06701,0841,1291,1131,2091,3541701932082332542692862843173333533903914054350
   > Total Current Assets 
0
435
405
391
390
353
333
317
284
286
269
254
233
208
193
170
376
209
64
52
12
0
62
53
549
485
331
323
222
2,017
10,508
9,367
8,084
5,836
10,938
53
15,449
53
14,452
121
12,819
9,083
5,478
4,245
2,542
3,002
2,251
1,662
1,155
568
345
304
3043455681,1551,6622,2513,0022,5424,2455,4789,08312,81912114,4525315,4495310,9385,8368,0849,36710,5082,017222323331485549536201252642093761701932082332542692862843173333533903914054350
       Cash And Cash Equivalents 
0
415
382
366
384
344
322
304
278
278
259
253
232
205
189
166
352
163
25
14
7
0
38
35
509
452
292
224
155
1,924
9,768
7,978
6,170
4,043
3,389
27
4,178
27
2,636
101
8,517
7,146
3,891
3,300
2,022
2,317
1,958
1,399
827
311
214
198
1982143118271,3991,9582,3172,0223,3003,8917,1468,5171012,636274,178273,3894,0436,1707,9789,7681,92415522429245250935380714251633521661892052322532592782783043223443843663824150
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
680
1,130
922
928
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000009289221,1306800000000000000000000000000000000
       Net Receivables 
0
20
23
25
5
9
11
13
6
8
10
1
2
3
4
5
15
29
35
39
5
0
24
19
40
30
38
95
60
90
100
97
123
127
144
16
682
16
716
20
138
199
243
443
111
318
208
237
230
184
83
83
838318423023720831811144324319913820716166821614412712397100906095383040192405393529155432110861311952523200
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10
0
10
0
0
3
8
1,166
315
305
291
0
0
0
0
48
23
234800002913053151,16683001001000000000000000002000000000000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
977
999
1,049
1,077
1,072
0
1,005
994
974
889
818
685
609
3,632
5,262
5,190
1,686
1,103
944
0
923
0
910
0
40,346
40,267
22,796
22,769
22,859
22,808
2,149
2,266
2,254
2,212
3,746
3,735
3,7353,7462,2122,2542,2662,14922,80822,85922,76922,79640,26740,3460910092309441,1031,6865,1905,2623,6326096858188899749941,00501,0721,0771,0499999770000000000000000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
261
374
475
528
585
0
639
699
739
719
710
639
609
3,632
5,262
5,190
1,686
1,103
944
0
893
0
831
0
1,187
1,109
117
107
97
88
89
79
69
58
48
37
37485869798988971071171,1091,1870831089309441,1031,6865,1905,2623,63260963971071973969963905855284753742610000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
269
267
268
263
254
1,479
1,468
1,434
0
0
001,4341,4681,479254263268267269000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
716
625
573
547
484
0
363
294
232
170
108
46
0
0
0
0
0
0
0
0
0
0
0
0
39,158
39,158
20,619
20,619
20,619
20,619
0
0
0
0
3,698
3,698
3,6983,698000020,61920,61920,61920,61939,15839,1580000000000004610817023229436304845475736257160000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,791
1,775
0
1,837
1,806
708
718
720
0
0
007207187081,8061,83701,7751,791000000000000000000000000000000000000000000
> Total Liabilities 
0
6
5
16
18
9
5
14
18
6
5
15
15
12
12
34
27
30
28
81
140
0
339
447
1,139
1,138
939
926
887
124
675
897
654
807
865
604
1,039
604
985
880
1,949
1,193
1,718
1,207
957
1,116
465
460
770
748
3,800
3,915
3,9153,8007487704604651,1169571,2071,7181,1931,9498809856041,0396048658076548976751248879269391,1381,1394473390140812830273412121515561814591816560
   > Total Current Liabilities 
0
6
5
16
18
9
5
14
18
6
5
15
15
12
12
34
27
30
28
81
140
0
339
447
116
115
51
97
38
124
675
897
654
807
865
604
1,039
604
985
880
1,657
909
1,718
1,207
957
1,116
465
460
770
748
915
1,030
1,0309157487704604651,1169571,2071,7189091,6578809856041,0396048658076548976751243897511151164473390140812830273412121515561814591816560
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
200
200
0
0
0
0
0
40
0
0
0
0
0
0
0
0
0
0
119
107
0
0
0
0
0
0
0
0
0
0
0000000000107119000000000040000002002000000000000000000000000
       Accounts payable 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
95
0
0
0
897
0
807
865
45
1,039
45
985
178
1,538
802
705
596
338
455
106
447
343
484
477
635
6354774843434471064553385967058021,538178985451,03945865807089700095000000000000000000000000000
       Other Current Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
139
220
0
102
51
95
38
84
0
0
0
0
0
0
0
0
0
0
0
0
1,718
1,040
790
948
0
0
0
264
438
395
3954382640009487901,0401,7180000000000008438955110202201390000000000000000000000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,023
1,023
888
829
849
0
0
0
0
0
0
0
0
0
0
0
291
284
0
0
0
0
0
0
0
0
2,885
2,885
2,8852,88500000000284291000000000008498298881,0231,023000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,885
2,885
2,8852,88500000000000000000000000000000000000000000000000000
> Total Stockholder Equity
0
429
400
375
371
343
328
304
267
281
265
238
218
195
180
136
1,327
1,179
1,085
1,048
944
0
728
600
384
235
210
82
-56
5,526
15,095
13,660
9,116
6,132
11,017
-551
15,333
-551
14,378
-760
51,216
48,160
26,559
25,810
24,447
24,697
3,938
3,471
2,643
2,035
294
128
1282942,0352,6433,4713,93824,69724,44725,81026,55948,16051,216-76014,378-55115,333-55111,0176,1329,11613,66015,0955,526-568221023538460072809441,0481,0851,1791,3271361801952182382652812673043283433713754004290
   Common Stock
0
0
0
514
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,956
0
0
0
11,744
0
11,819
11,819
596
11,744
596
11,744
597
46,652
60,562
56,894
57,333
57,333
60,813
62,012
62,012
62,012
62,012
62,867
63,101
63,10162,86762,01262,01262,01262,01260,81357,33357,33356,89460,56246,65259711,74459611,74459611,81911,819011,7440001,95600000000000000000000000514000
   Retained Earnings Total Equity0000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
59
0
0
0
59
59
38
38
38
38
38
38
38
39
186
186
202
202
0
202
202
194
222
222
222
222
1,564
10,126
11,599
12,412
12,577
12,671
0
13,067
0
13,079
0
27,715
15,671
13,451
13,134
13,154
13,658
14,056
14,057
14,103
14,116
14,120
14,118
14,11814,12014,11614,10314,05714,05613,65813,15413,13413,45115,67127,715013,079013,067012,67112,57712,41211,59910,1261,56422222222222219420220202022021861863938383838383838595900059000
   Capital Surplus 0000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
597
585
505
564
564
564
505
505
560
560
560
560
560
560
560
1,896
1,883
1,909
1,899
1,899
0
1,939
1,939
1,947
1,919
2,084
113
2,069
8,119
12,817
0
11,819
0
5,848
210
10,110
210
10,110
214
27,715
15,671
13,451
13,134
13,154
654
14,056
14,057
14,103
14,116
130
47
4713014,11614,10314,05714,05665413,15413,13413,45115,67127,71521410,11021010,1102105,848011,819012,8178,1192,0691132,0841,9191,9471,9391,93901,8991,8991,9091,8831,8965605605605605605605605055055645645645055855970



Balance Sheet

Currency in CAD. All numbers in thousands.




Cash Flow

All numbers in thousands.




Income Statement

Currency in CAD. All numbers in thousands.


Latest Income Statement (annual, 2022-05-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-42
Gross Profit-42-42
 
Operating Income (+$)
Gross Profit-42
Operating Expense-2,547
Operating Income-3,937-2,589
 
Operating Expense (+$)
Research Development0
Selling General Administrative2,378
Selling And Marketing Expenses128
Operating Expense2,5472,506
 
Net Interest Income (+$)
Interest Income94
Interest Expense-14
Other Finance Cost-0
Net Interest Income80
 
Pretax Income (+$)
Operating Income-3,937
Net Interest Income80
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-4,693-1,711
EBIT - interestExpense = -3,951
-6,162
-4,679
Interest Expense14
Earnings Before Interest and Taxes (EBIT)-3,937-4,679
Earnings Before Interest and Taxes (EBITDA)-3,895
 
After tax Income (+$)
Income Before Tax-4,693
Tax Provision-0
Net Income From Continuing Ops-4,693-4,693
Net Income-4,693
Net Income Applicable To Common Shares-4,693
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses2,547
Total Other Income/Expenses Net-2,225-80
 

Technical Analysis of Isracann
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Isracann. The general trend of Isracann is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Isracann's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Isracann Biosciences Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.005 < 0.005 < 0.005.

The bearish price targets are: 0.0001 > 0.0001 > 0.0001.

Tweet this
Isracann Biosciences Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Isracann Biosciences Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Isracann Biosciences Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Isracann Biosciences Inc. The current macd is -0.00088164.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Isracann price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Isracann. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Isracann price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Isracann Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) ChartIsracann Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Isracann Biosciences Inc. The current adx is 46.82.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Isracann shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Isracann Biosciences Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Isracann Biosciences Inc. The current sar is 0.00452921.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Isracann Biosciences Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Isracann Biosciences Inc. The current rsi is 24.93. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 1/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
Isracann Biosciences Inc Daily Relative Strength Index (RSI) ChartIsracann Biosciences Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Isracann Biosciences Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Isracann price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Isracann Biosciences Inc Daily Stochastic Oscillator ChartIsracann Biosciences Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Isracann Biosciences Inc. The current cci is -95.23809524.

Isracann Biosciences Inc Daily Commodity Channel Index (CCI) ChartIsracann Biosciences Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Isracann Biosciences Inc. The current cmo is -65.9915477.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Isracann Biosciences Inc Daily Chande Momentum Oscillator (CMO) ChartIsracann Biosciences Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Isracann Biosciences Inc. The current willr is -100.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Isracann Biosciences Inc Daily Williams %R ChartIsracann Biosciences Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Isracann Biosciences Inc.

Isracann Biosciences Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Isracann Biosciences Inc. The current atr is 0.00035677.

Isracann Biosciences Inc Daily Average True Range (ATR) ChartIsracann Biosciences Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Isracann Biosciences Inc. The current obv is 2,933,823.

Isracann Biosciences Inc Daily On-Balance Volume (OBV) ChartIsracann Biosciences Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Isracann Biosciences Inc. The current mfi is 0.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Isracann Biosciences Inc Daily Money Flow Index (MFI) ChartIsracann Biosciences Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Isracann Biosciences Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-29MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-02MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-14WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-19ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-22MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

Isracann Biosciences Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Isracann Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5024.931
Ma 20Greater thanMa 500.003
Ma 50Greater thanMa 1000.003
Ma 100Greater thanMa 2000.005
OpenGreater thanClose0.000
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Isracann with someone you think should read this too:
  • Are you bullish or bearish on Isracann? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Isracann? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Isracann Biosciences Inc

I send you an email if I find something interesting about Isracann Biosciences Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Isracann Biosciences Inc.

Receive notifications about Isracann Biosciences Inc in your mailbox!